Dendritic Cell Cancer Vaccine Market Size, Share & Trends Analysis Report By Products (CreaVax, Sipuleucel-T), By End-use (Pediatrics, Adults), By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Dendritic Cell Cancer Vaccine market was valued at USD 953.30 million in 2022 and it is expected to hit around USD 2.46 billion by 2030 with a CAGR of 13.18% during the forecast period 2022 to 2030.

Key Takeaways:

  • By products, Sipuleucel-T (Provenge) is expected to occupy the bigger share of market space due to demand to its advantages in the treatment of castrate-resistant prostate carcinoma.
  • By end use, adult segment is expected to grow rapidly over the forecast period owing to rise in incidence of carcinoma across the globe. The rise in the demand for personalized medicine for treatment of cancer, also positively impacts the growth of this segment.
  • North America dominated the global market in 2022, owing to rising prevalence of cancers, increasing healthcare expenditure and rising support for oncology research.
  • The Asia Pacific is expected to grow considerably in the future due to the rising prevalence of cancers and high population density. Moreover, key market players are working towards entering into Asia Pacific market with their dendritic cell vaccine expertise. For instance, in May 2021, BGI signed into an agreement with Ethiopian Biotechnology Institute to carryout pilot scale testing of HPV genotyping to establish a novel technique for HPV screening, diagnosis, and treatment.

The rising prevalence of cancer and technological improvement such as drug innovation related to cancer driving the market growth. According to the WHO, cancer is the leading cause of mortality globally, accounting around 10 million deaths in 2020.

Immunotherapy is a new approach that strengthens individual’s immunity to combat different types of carcinoma. Dendritic cell-based immunotherapy vaccination is a well-known and approved approach for enhancing the potential of immune system to eliminate tumor cells. Many studies are carried out to gauge the efficacy of dendritic cell cancer vaccines. For instance, in June 2020, UbiVac, Inc. signed into a clinical trial collaboration with Bristol Myers Squibb for evaluation of the safety, tolerability, and preliminary efficacy of UbiVac’s investigational product (DPV-001), a dendritic cell-targeted micro-vesicle containing short-lived protein vaccine to explore autophagy, in combination with anti-OX40 (by Bristol Myers Squibb) along with sequenced administration of nivolumab.

Moreover, wide applications of cancer vaccines to boost the immune system are some of the driving factors for market growth. Cancer vaccines are appropriately recognizing and effectively react to antigens associated with carcinoma and kill the carcinogenic cells. They progressively reduce the growth of tumorous cells in the body and induce immunity in an individual to effectively cease the chances of a relapse of cancer condition.

Rising clinical trial activity along with novel product launches create the growth opportunity for market growth. As of November 2022, more than 80 dendritic cell cancer vaccines are under clinical trials. In addition, in June 2021, SPAG9, India's First Indigenous Tumor Antigen, Received a Trademark from DBT-NII. Dendritic cell (DC)-based immunotherapy is being used with ASPAGNIITM for cervical, ovarian, and breast cancers.

Furthermore, key companies in the market undertaking various strategic initiatives to introduce novel are expected to drive the market. For instance, in June 2020, Saint-Gobain Life Sciences signed into a joint collaboration with Kanyr Pharma Inc., the RI-MUHC and McGill University for research on cancer vaccines based on dendritic cells using single-use culture containers by Saint-Gobain for R&D, clinical-scale and commercial phase production of vaccines.

Report Scope of the Dendritic Cell Cancer Vaccine Market

Report Coverage

Details

Market Size

USD 2.46 Billion by 2030

Growth Rate

CAGR of 13.18% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year

2021

Forecast Period

2022 to 2030

Segments Covered

Product, end-use, and Region,

Companies Mentioned

3M company; GlaxoSmithKline plc; Activartis; Batavia Bioservices; Argos Therapeutics; Sanpower Corporation; Elios Therapeutics; DanDrit Biotech; DCPrime; ImmunoCellular Therapeutics

 

Product Insights

The Sipuleucel-T (Provenge) segment held the largest share in 2022. The ability of Sipuleucel-T to effectively enhance individual’s immunity against tumor cells is increasing its market demand. The vaccine was approved for usage in 2010 by the U.S. FDA for the treatment of castrate-resistant prostate carcinoma. Many studies have shown positive inferences by using Sipuleucel-T in terms of immunity, minimal side effects and increase in the lifespan of a survivor. For instance, in October 2020, Dendreon Pharmaceuticals, declares the publication of an analysis that examined the real-world survival outcomes in men with metastatic castrate-resistant prostate carcinoma on treatment with Sipuleucel-T and other associative oral medications.

The CreaVax is anticipated to grow significantly during the forecast period. It is autologous dendritic cell-based cancer vaccine is created from peripheral blood mononuclear cells (PBMC) of the patient and sensitised with tumour lysate and KLH before developing into dendritic cells (Keyhole Limpet Hemocyanin). The Creavax is a therapeutic vaccine for renal cell carcinoma produced by Creagene in 2007. CreaVax is currently under Phase III clinical trial investigation for its utility in treatment of hepatocellular carcinoma.

End-use Insights

The adult vaccines segment held the highest market share in 2022 owing to rising incidence of cancers across the globe. Moreover, many researchers across the globe are carrying out extensive research for the development of effective vaccine candidates to achieve the potential therapeutic strategies. For instance, in March 2022, Maryland-based Northwest Biotherapeutics declares the initiation of the production of first personalized dendritic cell-based cancer vaccine at its new production facility in Sawston, UK using advanced therapy medicinal products for the treatment of a glioblastoma case on compassion.

The pediatric vaccine segment is anticipated to grow significantly during the forecast period. Dendritic cell cancer vaccines are used to boost the immune mechanism of an individual at an early age, so as to eliminate the chances of tumor initiation and progression.

Regional Insights

North America leads the global dendritic cell cancer vaccine market in 2022. The growth of the dendritic cell cancer vaccine market in the region is mainly attributed to unprecedented rise in the incidence of cancer cases and extensive research studies sponsored by academic research institutes and pharmaceutical giants. For instance, in May 2022, researchers at the Memorial Sloan Kettering Cancer Centre, U.S. have been researching upon mRNA vaccine technology and will be presenting results from the phase-1 trial at the annual meeting of the American Society of Clinical Oncology. mRNA vaccines are known to induce dendritic cells to make the neo-antigen proteins against carcinogenic cells.

Europe is anticipated to show significant market growth in the coming years. This is attributed to growing demand for cancer vaccines, the rising incidence of cancer, rise in support for research studies from cancer societies across Europe, and emerging market players in the region positively impacts the growth of the dendritic cell cancer vaccine market.

Some of the prominent players in the Dendritic Cell Cancer Vaccine Market include:

  • GlaxoSmithKline plc,
  • 3M company
  • Activartis
  • Batavia Bioservices,
  • Argos Therapeutics
  • Sanpower Corporation
  • Elios Therapeutics
  • DanDrit Biotech
  • DCPrime
  • ImmunoCellular Therapeutics

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Dendritic Cell Cancer Vaccine market

  • Product
    • CreaVax
    • Sipuleucel-T (Provenge)
    • Other
  • End-use
    • Pediatrics
    • Adults

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Dendritic Cell Cancer Vaccine industry analysis from 2022 to 2030 to identify the prevailing Dendritic Cell Cancer Vaccine industry opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global Dendritic Cell Cancer Vaccine industry segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global Dendritic Cell Cancer Vaccine industry trends, key players, market segments, application areas, and market growth strategies.

Report Detail

  • Report Code:7548
  • No. of Pages:
  • Format:PDF/PPT/Excel

Proceed To Buy

USD 3500
USD 7000